Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Agrees to Acquire RayThera for Up to $1B | Contract Pharma

What are you searching for?

Sign in
Breaking News

Biogen Agrees to Acquire RayThera for Up to $1B

RayThera’s portfolio includes multiple anti-inflammatory assets that could potentially treat immune-mediated conditions across a range of indications.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Editor’s Take: The M&A market continues to move at a rapid pace. Recently, GSK’s acquisition of Nuvalent Inc. for $10.6 billion was the second largest acquisition of the year.

Biogen Inc. has agreed to acquire RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology, for up to $1 billion, consisting of an upfront payment and payments contingent on the achievement of future clinical and regulatory milestones.

RayThera’s portfolio includes multiple anti-inflammatory assets that could potentially treat immune-mediated conditions across a range of indications. The lead candidate is expected to enter Phase 1 development in early Q3 2026.

“With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas,” said Priya Singhal, M.D., M.P.H., EVP and Head of Development at Biogen. “We believe these assets can meaningfully contribute to our long-term pipeline potential and we’re excited about the opportunity to rapidly advance the first candidate into the clinic.”

The transaction is currently anticipated to close in the third quarter of 2026. With the acquisition, once closed, Biogen will lead development, manufacturing and global commercialization of these assets.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics